ENTRY       D02598                      Drug
NAME        Infliximab (USAN/INN);
            Infliximab (genetical recombination) (JAN);
            Infliximab (genetical recombination) [Infliximab biosimilar 1] (JAN);
            Infliximab (genetical recombination) [Infliximab biosimilar 2] (JAN);
            Infliximab (genetical recombination) [Infliximab biosimilar 3] (JAN);
            Infliximab-dyyb;
            Infliximab-abda;
            Infliximab-axxq;
            Remicade (TN);
            Inflectra (TN);
            Renflexis (TN);
            Avsola (TN)
PRODUCT     AVSOLA (Amgen)
            INFLECTRA (Pfizer Laboratories Div Pfizer)
            INFLIXIMAB (Janssen Biotech)
            REMICADE (Janssen Biotech)
            RENFLEXIS (Merck Sharp & Dohme LLC)
            RENFLEXIS (Organon LLC)
CLASS       Anti-inflammatory
             DG01985  Disease modifying anti-rheumatic drug (DMARD)
              DG01936  TNF inhibitor
REMARK      Therapeutic category: 2399
            ATC code: L04AB02
            Product: D02598<JP/US>
EFFICACY    Anti-inflammatory, Antirheumatic, Anti-TNF-alpha antibody
  DISEASE   Crohn's disease [DS:H00286]
            Ulcerative colitis [DS:H01466]
            Rheumatoid arthritis [DS:H00630]
            Ankylosing spondylitis [DS:H01674]
            Psoriatic arthritis [DS:H01507]
            Plaque psoriasis [DS:H01656]
  TYPE      Monoclonal antibody
TARGET      TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156]
  PATHWAY   hsa04010(7124)  MAPK signaling pathway
            hsa04060(7124)  Cytokine-cytokine receptor interaction
            hsa04210(7124)  Apoptosis
            hsa04350(7124)  TGF-beta signaling pathway
            hsa04380(7124)  Osteoclast differentiation
            hsa04612(7124)  Antigen processing and presentation
            hsa04920(7124)  Adipocytokine signaling pathway
            hsa05321(7124)  Inflammatory bowel disease
            hsa05323(7124)  Rheumatoid arthritis
INTERACTION  
STR_MAP     map07050  Antirheumatics - DMARDs and biological agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
                 L04AB02 Infliximab
                  D02598  Infliximab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunosuppressants
               Tumor Necrosis Factor (TNF) Blockers
                Infliximab
                 D02598  Infliximab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              23  Digestive organ agents
               239  Miscellaneous
                2399  Others
                 D02598  Infliximab (USAN/INN); Infliximab (genetical recombination) (JAN); Infliximab (genetical recombination) [Infliximab biosimilar 1] (JAN); Infliximab (genetical recombination) [Infliximab biosimilar 2] (JAN); Infliximab (genetical recombination) [Infliximab biosimilar 3] (JAN)
            Drug groups [BR:br08330]
             Anti-inflammatory
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               DG01936  TNF inhibitor
                D02598  Infliximab
            Drug classes [BR:br08332]
             Immunological agent
              DG01936  TNF inhibitor
               D02598  Infliximab
             Antirheumatic agent
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D02598  Infliximab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Tumor necrosis factors
                TNF (TNFA, TNFSF2)
                 D02598  Infliximab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D02598
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D02598
DBLINKS     CAS: 170277-31-3
            PubChem: 17396768
            NIKKAJI: J2.104.914J
///
